Literature DB >> 22941400

Morphological parameters of flat epithelial atypia (FEA) in stereotactic vacuum-assisted needle core biopsies do not predict the presence of malignancy on subsequent surgical excision.

Simonetta Bianchi1, Benedetta Bendinelli, Isabella Castellano, Quirino Piubello, Giuseppe Renne, Maria Grazia Cattani, Domenica Di Stefano, Giovanna Carrillo, Licia Laurino, Alessandra Bersiga, Carmela Giardina, Stefania Dante, Carla Di Loreto, Carmela Quero, Concetta Maria Antonacci, Domenico Palli.   

Abstract

Flat epithelial atypia (FEA) may represent the earliest precursor of low-grade breast cancer and often coexists with more advanced atypical proliferative breast lesions such as atypical ductal hyperplasia (ADH) and lobular intraepithelial neoplasia (LIN). The present study aims to investigate the association between morphological parameters of FEA and presence of malignancy at surgical excision (SE) and the clinical significance of the association of FEA with ADH and/or LIN. This study included 589 cases of stereotactic 11-gauge vacuum-assisted needle core biopsy (VANCB), reporting a diagnosis of FEA, ADH or LIN with subsequent SE from 14 pathology departments in Italy. Available slides were reviewed, with 114 (19.4 %) showing a malignant outcome at SE. Among the 190 cases of pure FEA, no statistically significant association emerged between clinical-pathological parameters of FEA and risk of malignancy. Logistic regression analyses showed an increased risk of malignancy according to the extension of ADH among the 275 cases of FEA associated with ADH (p = 0.004) and among the 34 cases of FEA associated with ADH and LIN (p = 0.02). In the whole series, a statistically significant increased malignancy risk emerged according to mammographic R1-R3/R4-R5 categories (OR = 1.56; p = 0.04), extension (OR = 1.24; p = 0.04) and grade (OR = 1.94; p = 0.004) of cytological atypia of FEA. The presence of ADH was associated with an increased malignancy risk (OR = 2.85; p < 0.0001). Our data confirm the frequent association of FEA with ADH and/or LIN. A diagnosis of pure FEA on VANCB carries a 9.5 % risk of concurrent malignancy and thus warrants follow-up excision because none of the clinical-pathological parameters predicts which cases will present carcinoma on SE.

Entities:  

Mesh:

Year:  2012        PMID: 22941400     DOI: 10.1007/s00428-012-1279-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  Columnar cell hyperplasia is associated with lobular carcinoma in situ and tubular carcinoma.

Authors:  P P Rosen
Journal:  Am J Surg Pathol       Date:  1999-12       Impact factor: 6.394

2.  Flat epithelial atypia on breast needle core biopsy: a retrospective study with clinical-pathological correlation.

Authors:  Tsu-Yee Joseph Lee; Rebecca F Macintosh; Daniel Rayson; Penny J Barnes
Journal:  Breast J       Date:  2010-04-29       Impact factor: 2.431

Review 3.  Flat epithelial atypia of the breast: characteristics and behaviors.

Authors:  Monisha Sudarshan; Ari-Nareg Meguerditchian; Benoit Mesurolle; Sarkis Meterissian
Journal:  Am J Surg       Date:  2010-09-22       Impact factor: 2.565

4.  BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value.

Authors:  Elizabeth Lazarus; Martha B Mainiero; Barbara Schepps; Susan L Koelliker; Linda S Livingston
Journal:  Radiology       Date:  2006-03-28       Impact factor: 11.105

5.  Flat epithelial atypia (DIN 1a, atypical columnar change): an underdiagnosed entity very frequently coexisting with lobular neoplasia.

Authors:  S Leibl; P Regitnig; F Moinfar
Journal:  Histopathology       Date:  2007-06       Impact factor: 5.087

Review 6.  Columnar cell lesions on breast needle biopsies: is surgical excision necessary? A systematic review.

Authors:  Anoek H J Verschuur-Maes; Carolien H M van Deurzen; Evelyn M Monninkhof; Paul J van Diest
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

7.  Core biopsy of the breast with atypical ductal hyperplasia: a probabilistic approach to reporting.

Authors:  K A Ely; B A Carter; R A Jensen; J F Simpson; D L Page
Journal:  Am J Surg Pathol       Date:  2001-08       Impact factor: 6.394

Review 8.  Flat epithelial atypia of the breast.

Authors:  Melinda F Lerwill
Journal:  Arch Pathol Lab Med       Date:  2008-04       Impact factor: 5.534

9.  Columnar cell lesions and subsequent breast cancer risk: a nested case-control study.

Authors:  Sarah A Aroner; Laura C Collins; Stuart J Schnitt; James L Connolly; Graham A Colditz; Rulla M Tamimi
Journal:  Breast Cancer Res       Date:  2010-08-06       Impact factor: 6.466

10.  Flat DIN 1 (flat epithelial atypia) on core needle biopsy: 63 cases identified retrospectively among 1,751 core biopsies performed over an 8-year period (1992-1999).

Authors:  Maritza Martel; Patricia Barron-Rodriguez; Idris Tolgay Ocal; Jorge Dotto; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.535

View more
  10 in total

1.  Upgrade Rate of Pure Flat Epithelial Atypia Diagnosed at Core Needle Biopsy: A Systematic Review and Meta-Analysis.

Authors:  Rifat A Wahab; Su-Ju Lee; Margaret E Mulligan; Bin Zhang; Mary C Mahoney
Journal:  Radiol Imaging Cancer       Date:  2021-01-22

2.  Flat epithelial atypia and risk of breast cancer: A Mayo cohort study.

Authors:  Samar M Said; Daniel W Visscher; Aziza Nassar; Ryan D Frank; Robert A Vierkant; Marlene H Frost; Karthik Ghosh; Derek C Radisky; Lynn C Hartmann; Amy C Degnim
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

Review 3.  How Do We Approach Benign Proliferative Lesions?

Authors:  Faina Nakhlis
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

Review 4.  Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review.

Authors:  Kelly L Mooney; Lawrence W Bassett; Sophia K Apple
Journal:  Mod Pathol       Date:  2016-08-19       Impact factor: 7.842

5.  Is the outcome at surgery different when flat epithelial atypia and lobular neoplasia are found in association at biopsy?

Authors:  Mona El Khoury; Lilia Maria Sanchez; Lucie Lalonde; Isabelle Trop; Julie David; Benoît Mesurolle
Journal:  Br J Radiol       Date:  2017-03-03       Impact factor: 3.039

6.  Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies.

Authors:  Benjamin C Calhoun; Amy Sobel; Richard L White; Matt Gromet; Teresa Flippo; Terry Sarantou; Chad A Livasy
Journal:  Mod Pathol       Date:  2014-11-21       Impact factor: 7.842

7.  Flat epithelial atypia: conservative management of patients without residual microcalcifications post-vacuum-assisted breast biopsy.

Authors:  Simone Schiaffino; Licia Gristina; Alessandro Villa; Simona Tosto; Francesco Monetti; Franca Carli; Massimo Calabrese
Journal:  Br J Radiol       Date:  2017-11-09       Impact factor: 3.039

Review 8.  Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended?

Authors:  Marco Lucioni; Chiara Rossi; Pascal Lomoro; Francesco Ballati; Marianna Fanizza; Alberta Ferrari; Carlos A Garcia-Etienne; Emanuela Boveri; Giulia Meloni; Maria Grazia Sommaruga; Elisa Ferraris; Angioletta Lasagna; Elisabetta Bonzano; Marco Paulli; Adele Sgarella; Giuseppe Di Giulio
Journal:  Eur Radiol       Date:  2020-08-20       Impact factor: 5.315

9.  Flat Epithelial Atypia in Breast Core Needle Biopsies With Radiologic-Pathologic Concordance: Is Excision Necessary?

Authors:  Anne Grabenstetter; Sandra Brennan; Elena D Salagean; Monica Morrow; Edi Brogi
Journal:  Am J Surg Pathol       Date:  2020-02       Impact factor: 6.298

Review 10.  Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?

Authors:  Sarah Strickland; Gulisa Turashvili
Journal:  Curr Oncol       Date:  2022-08-11       Impact factor: 3.109

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.